Related Experiment Video
Updated: Sep 21, 2025

07:56
Genome Editing in Mammalian Cell Lines using CRISPR-Cas
Published on: April 11, 2019
22.1K
Development of an efficient iterative genome editing method in Bacillus subtilis using the CRISPR-AsCpf1 system
Xingcong Zhao1, Xi Chen1, Yanbing Xue1
1State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
Journal of Basic Microbiology
|June 3, 2022
Summary
We developed a CRISPR-AsCpf1 system for efficient genome editing in Bacillus subtilis, enabling precise gene insertion and deletion for enhanced chemical production. This system achieved high editing efficiencies and facilitated the heterologous production of hyaluronic acid.
Area of Science:
- Synthetic biology
- Metabolic engineering
- Microbial biotechnology
Background:
- Bacillus subtilis is a versatile microbial chassis for producing valuable chemicals.
- Iterative genome editing is crucial for optimizing microbial strains but can be challenging.
- Existing genome editing tools may lack efficiency or require complex procedures.
Purpose of the Study:
- To develop and validate a novel CRISPR-AsCpf1-based system for efficient and iterative genome editing in Bacillus subtilis.
- To demonstrate the system's utility for genetic modifications related to hyaluronic acid biosynthesis.
- To engineer a B. subtilis strain for heterologous hyaluronic acid production.
Main Methods:
- Construction of CRISPR-AsCpf1 expression plasmids utilizing a temperature-sensitive replicon.
- Application of the system for gene insertion (hasA, tuaD) and large genomic deletion (eps gene cluster).
- Assessment of editing efficiency and plasmid curing for iterative modifications.
Main Results:
- Achieved high genome editing efficiencies (80%-100%) for gene insertion and deletion in B. subtilis 168.
- Successfully implemented iterative genome engineering for hyaluronic acid (HA) biosynthesis pathway.
- Engineered B. subtilis strain produced 1.39 g/L of heterologous hyaluronic acid.
Conclusions:
- The developed CRISPR-AsCpf1 system offers a highly efficient and rapid method for bacterial genome engineering.
- This system provides valuable tools and guidance for optimizing B. subtilis for industrial applications.
- The successful HA production demonstrates the system's potential for metabolic engineering and chemical synthesis.
Related Concept Videos
CRISPR/Cas9 Genome Editing
431
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
431
CRISPR
53.0K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
53.0K
CRISPR and crRNAs
17.5K
Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
17.5K

